CARDISURE 1.25MG 100PK

Target species Dogs. Indications for use For the treatment of canine congestive heart failure originating from valvular insufficiency (mitral and/or tricuspid regurgitation) or dilated cardiomyopathy. Contraindications Do not use in cases of hypertrophic cardiomyopathies or clinical conditions where an augmentation of cardiac output is not possible for functional or anatomical reasons (e.g. aortic stenosis). See also Use during pregnancy and lactation. Special warnings for each target species The product should be administered on an empty stomach at least one hour before meals, as absorption is reduced when given with feed. The product is flavoured. To avoid accidental ingestion the tablets should be stored out of reach of dogs. An in vitro study in rat tissue demonstrated that pimobendan increased glucose-induced insulin release from pancreatic β-cells in a dose-dependent manner. If the product is administered to diabetic dogs, blood glucose levels should be carefully monitored. As pimobendan is metabolised in the liver, particular care should be taken when administering the product to dogs with severe hepatic insufficiency. Monitoring of cardiac function and morphology is recommended in animals treated with pimobendan.(See also Adverse reactions). Special precautions to be taken by the person administering the veterinary medicinal product to animals. In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician. Wash hands after use. Advice to doctors: accidental ingestion, especially by a child, may lead to the occurrence of tachycardia, orthostatic hypotension, flushing of the face and headaches. Adverse reactions A moderate positive chronotropic effect and vomiting may occur in rare cases. However, these effects are dose-dependent and may be avoided by reducing the dose in these cases. In rare cases transient diarrhoea, anorexia or lethargy have been observed. Although a relationship with pimobendan has not been clearly established, in very rare cases, signs of effects on primary haemostasis (petechiae on mucous membranes, subcutaneous haemorrhages) may be observed during treatment. These signs disappear when the treatment is withdrawn. In rare cases, an increase in mitral valve regurgitation has been observed during chronic pimobendan treatment in dogs with mitral valve disease. The frequency of adverse reactions is defined using the following convention: -very common (more than 1 in 10 animals displaying adverse reactions during the course of one treatment) -common (more than 1 but less than 10 animals in 100 animals) -uncommon (more than 1 but less than 10 animals in 1,000 animals) -rare (more than 1 but less than 10 animals in 10,000 animals) -very rare (less than 1 animal in 10,000 animals, including isolated reports). Use during pregnancy and lactation Laboratory studies in rats and rabbits have not produced any evidence of teratogenic or foetotoxic effects. However, these studies have shown evidence of maternotoxic and embryotoxic effects at high doses, and have also shown that pimobendan is excreted into milk. The safety of the product has not been assessed in pregnant or nursing bitches. Use only according to the benefit/risk assessment by the responsible veterinarian. Interactions In pharmacological studies no interaction between the cardiac glycoside ouabain and pimobendan was detected. The pimobendan-induced increase in contractility of the heart is attenuated in the presence of the calcium antagonist verapamil and the β-antagonist propranolol.